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Objectives: Binge Eating Disorder (BED) recently moved, with slight modifica-
tion, from the DSM-IV appendix to a fully recognized disorder in DSM-5. There 
is limited information on the impact of BED on productivity and social function-
ing. One cross-national epidemiological study reported BED was associated with 
an increased number of days of role impairment. We report here the associations 
of DSM-5 defined BED, with work productivity and functional impairment in the 
work/school, social and family life domains. MethOds: An Internet survey of a 
representative sample of US adults, conducted in fall, 2013, included questions 
related to demographics, general health, psychiatric comorbidities, assessment for 
DSM-5 criteria for BED, the Work Productivity and Activity Impairment questionnaire 
(WPAI) and the Sheehan Disability Scale (SDS). SDS and WPAI were compared (BED 
vs no BED groups) via ANOVA. Results: Among 22,397 respondents, 344 (1.5%) 
participants (242 women and 102 men) met full DSM-5 criteria for BED, 1,616 (7.2%) 
reported overeating with loss of control but not meeting DSM-V criteria for BED. 
The remainder of the respondents, 20,437 (91.3%), may have reported overeating but 
no other BED symptoms. Relative to those with no BED, those with BED had higher 
mean[SD] impairment on SDS work/school (3.86[3.62]) vs 1.01[2.21], p< 0.001), social 
life (5.29[3.49] vs 1.22[2.33], p< 0.001) and home/family life (4.89[3.44] vs 1.18[2.26], 
p< 0.001). As measured by WPAI, those with BED, compared to those in the no BED 
group, had higher mean[SD] scores for absenteeism (9.59[19.97] vs 2.90[12.95]), 
presenteeism (30.00[31.64] vs 10.86[20.07]), work productivity loss (33.19[33.85] vs 
12.60[23.22]), and activity impairment (43.52[34.36] vs 19.94[27.22]) respectively 
(p< 0.001 for all). cOnclusiOns: This is the first large population study to examine 
the association of BED, using DSM-5 criteria, with work productivity and daily func-
tioning. Results suggest that those with BED experience considerable impairment 
in functioning and work productivity relative to those without BED.
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Objectives: The adjunctive use of some atypical antipsychotics (AAPs) has shown 
to provide some benefits in improving the depressive symptoms in patients with 
treatment-resistant depression. However, little is known about the impact of these 
agents on patients’ health-related quality of life (HRQoL). MethOds: Patients 
with self-reported depression (ICD-9: 296, 300, and 311), and have used the given 
AAPs and/or antidepressants for at least a year, were identified in the Medical 
Expenditure Panel Survey (MEPS) of 2008-2011. The patients were classified into 
users of adjunctive AAPs (i.e., antidepressants plus AAPs) and users of antidepres-
sants only. The AAPs were identified based on documented evidence, and included 
risperidone, aripiprazole, quetiapine, olanzapine, and ziprasidone. Multivariate 
linear regression analyses were conducted to determine whether the utilization 
of AAPs was associated with the Physical Component Summary-12 (PCS12) or with 
Mental Component Summary-12 (MCS-12) of HRQoL measure. Socio-demographics, 
Charlson Comorbidity Index, psychotherapy (i.e., cognitive behavioral therapy), 
Patient Health Questionniare-2 (PHQ-2) scores, and the number of prescription 
medications associated with depression were controlled. Results: A total of 3,638 
participants reported to have depression and to have used the given AAPs and/or 
antidepressants for at least a year during the period of 2008-2011 (306 on AAPs vs. 
3,332 on antidepressants only). The study subjects were ≥ 18 years, predominately 
White (91.9%) and female (71%). The adjunctive AAPs utilization was not associated 
with higher scores in the PCS-12 (β = 1.455, 95% CI = − 0.1366-3.0459, p = 0.0729). 
Rather, it was negatively associated with the MCS-12 scores (β = − 1.549, 95% CI 
= − 3.0171-− 0.0822, p = 0.0386). cOnclusiOns: The adjunctive utilization of AAPs 
was not associated with higher scores of HRQoL. Future studies should examine 
whether poor mental scores of HRQoL have occurred from lower medication adher-
ence to AAPs or from lower baseline HRQoL scores among users of adjunctive AAPs.
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Objectives: People with dementia are sensitive to cognitive side effects of 
anticholinergic drugs and this may adversely affect their Health Related Quality of 
Life (HRQoL). The study examined the association between the use of drugs with 
anticholinergic properties and HRQoL among community-dwelling elderly dementia 
patients. MethOds: This was a retrospective longitudinal cohort study involving 
elderly (age> = 65 years) patients with a diagnosis of dementia, using data from 
Medical Expenditure Panel Survey (MEPS) panels 9 to 13. Each panel consisted of 
five rounds which spanned over the period of two years. Patients who used anticho-
linergic drugs in round 1 or 2 were excluded. Anticholinergic drug exposure was 
measured in rounds 3 and 4 using Anticholinergic Drug Scale (ADS), an ordinal scale 
that rates anticholinergic drugs into levels 0 - 3 in increasing order of anticholinergic 
potency. The outcomes of interest were Physical Component Score (PCS) and Mental 
Component Score (MCS) based on Short-Form 12 (SF-12) health survey, measured 
in round 4. Two separate multiple linear regressions analyses were performed to 
determine the association of anticholinergic drugs with PCS and MCS while adjust-
ing for sociodemographic variables and baseline HRQoL measures. Results: The 
study included 112 patients, of which, 15.18% used anticholinergic drugs. Majority 
of the study participants were between ages of 65-79 (53%), females (57%), and with 
poor or low family income (65%). After controlling for sociodemographic and base-
line characteristics, anticholinergic drug use was significantly associated with 5.75 
units reduction in PCS (p-value: 0.01) whereas no association was found between 
anticholinergic use and MCS. Baseline HRQoL measures were found significant in 
both models. cOnclusiOns: Anticholinergic medications were associated with 
item Medical Outcomes Study Short-Form Health Survey version 2 (SF-12v2) among 
adults with autism. MethOds: Study data was collected using an online survey 
(Qualtrics software system) of 291 adults with autism registered with the Interactive 
Autism Network (IAN). Using confirmatory factor analysis, construct validity of the 
SF-12v2 was examined by comparing model fits across four different iterations of 
the SF-12v2 two-factor structure. Known-groups validity was assessed by compar-
ing SF-12v2 physical component summary (PCS) and mental component summary 
(MCS) score by autism severity. Internal consistency reliability was determined using 
Cronbach’s alpha. Floor and ceiling effects were assessed based on the percentage of 
participants scoring the lowest and highest possible score, respectively. Results: 
Results from CFA indicated an adequate fit with the data for the two-factor SF-12v2 
model with minor modifications. As per known-groups validity, the SF-12v2 MCS 
domain adequately distinguished adults with autism by severity, with higher MCS 
score observed among adults with low autism severity as compared to those with 
high autism severity. However, contrary results were observed for the PCS domain. 
High internal consistency reliability was observed for the PCS domain (Cronbach’s 
alpha 0.87), MCS domain (Cronbach’s alpha 0.73), and overall instrument (Cronbach’s 
alpha 0.84). There were no floor and ceiling effects. cOnclusiOns: The SF-12v2 had 
good construct validity, and the factor structure fit well with the data. The known-
groups validity of the SF-12v2 warrants further investigation in this population. 
Reliability of the instrument was good, and there were no floor and ceiling effects. 
Overall, SF-12v2 had adequate psychometric properties among adults with autism.
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Objectives: To assess the content validity and patient interpretation of the Self-
Reported Misuse, Abuse and Diversion (SR-MAD) of Prescription (Rx) Opioids instru-
ment. MethOds: A cross-sectional, qualitative study was conducted in patients 
with chronic or acute pain. Patients were recruited from 3 clinical sites based on 
three patient groups (opioid naïve, known opioid abusers, and chronic opioid non-
abusers) to participate in a one-on-one cognitive interview. Patients completed the 
SR-MAD instrument via web-administration and then participated in an in-depth 
discussion following a semi-structured interview guide to assess the patient’s 
understanding of the questionnaire. Descriptive statistics and content analysis were 
performed. Results: Thirty-seven patients were interviewed: 11 opioid naïve; 13 
known abusers; and 13 non-abusers. Mean age was 55 ± 13.5 years (range 26 to 84); 
33 patients (89%) experienced chronic pain, three (8%) experienced acute pain, and 
one (3%) experienced both chronic and acute pain. Overall, most patients (n= 31, 84%) 
demonstrated a comprehensive understanding of the questionnaire’s content and 
reported the SR-MAD was easy to complete via web-administration. The majority of 
patients (n= 28, 76%) reported they were truthful when completing the questionnaire 
and most (n= 22, 59%) said they were comfortable completing the questionnaire 
using a secure internet site. Although some patients (n= 15, 41% [opioid naïve n= 5, 
known abusers n= 7, and non-abusers n= 3]) reported there were questions about 
opioid misuse that were not applicable to them, they all understood what was 
being asked and thought the questions would be relevant if they were abusing pain 
medication. Eight patients (known abusers n= 4, non-abusers n= 1, opioid naïve n= 3) 
reported they were not comfortable answering the SR-MAD honestly in a clinic/doc-
tor’s office. cOnclusiOns: The SR-MAD was developed based on patient input and 
addresses opioid abuse, misuse, and diversion. Additional interviews with aberrant 
opioid abusers are underway to further examine the content validity of the SR-MAD.
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Objectives: The purpose of this study was to determine the predictors of quality of 
life (QOL) among adults with autism. A modified version of Wilson and Cleary’s QOL 
conceptual model was used to study the relationship between autism severity, coping, 
functional independence, social support and QOL in adults with autism. MethOds: 
A cross-sectional, descriptive quantitative design was utilized for this study. An inter-
net-based survey using Qualtrics online software system was administered to adults 
with autism enrolled with the Interactive Autism Network (IAN). Among these adults, 
those who were: 1) aged 18 years and above; and 2) capable of self-reporting with little 
or no proxy help were identified and approached for participation. Structural equation 
modeling (SEM) was used to identify the inter-relationship among study variables 
and to identify the factors influencing QOL among adults with autism. Results: 
The survey sample included 262 adults with autism. Results from the SEM analysis 
revealed the modified Wilson and Cleary’s QOL model tested in the study to have an 
adequate fit (chi-square= 49.75, df= 17; RMSEA= 0.88; CFI= 0.95). Significant correlations 
among coping, functional independence, social support and QOL domains (p< 0.05) 
were observed. Study results depicted autism severity, maladaptive coping, appraisal 
social support and functional independence as significant predictors of physical and 
environment QOL. Autism severity had a significant (p< 0.05) negative impact on 
physical, psychological and environment QOL. Higher degree of social support and 
adaptive coping were found to have a positive influence on QOL. cOnclusiOns: 
Modifiable variables including social support and coping were found to influence QOL 
among adults with autism. Physicians and other health care professionals involved in 
the management of autism among these adults should consider these factors when 
designing treatment intervention strategies.
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